(MedPage Today) — Adding simvastatin and rifaximin to standard therapy for decompensated cirrhosis does not improve clinical outcomes, a double-blind phase III trial showed.
For the primary endpoint, no significant difference emerged for the…
Source link : https://www.medpagetoday.com/gastroenterology/generalhepatology/114092
Author :
Publish date : 2025-02-05 18:13:28
Copyright for syndicated content belongs to the linked Source.
